Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in PatientsWith Chronic Heart Failure

Author(s):
Voors, A.A.; Dungen, H.D.; Senni, M.; Nodari, S.; Agostoni, P.; Ponikowski, P.; Bax, J.J.; Butler, J.; Kim, R.J.; Dorhout, B.; Dinh, W.; Gheorghiade, M.
Published
2017
Publication type
Article / Letter to editor
heart failurepartial adenosine A1 receptor agonistcardioprotectionAV blockneladenoson bialanate
Date issued
2017-04-30
Language
English
Is part of
Journal of Clinical Pharmacology (2017), Vol. 57, no. 4, p. 440-451
hdl
1887/95044
doi
10.1002/jcph.828